Immunocapture enzyme activity assay
RatTRAP™ (TRAcP 5b) ELISA assay is a solid-phase enzyme activity assay for the determination of osteoclast-derived-tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) in rat serum samples. It can be used with rat osteoclast culture media.
High amounts of tartrate-resistant acid phosphatase (TRACP) are expressed by bone-resorbing osteoclasts and activated macrophages. Two forms of TRACP circulate in blood, known as TRACP 5a and TRACP 5b.
TRACP 5b is derived from osteoclasts and TRACP 5a from inflammatory macrophages. Osteoclasts secrete TRACP 5b into the blood circulation as an active enzyme that is inactivated and degraded to fragments before it is removed from the circulation. Thus, TRACP 5b activity does not accumulate into the circulation in renal or hepatic failure. Diurnal variability of serum TRACP 5b is low and the levels are not affected by feeding, allowing sample collection at any time of day.
Recent studies have shown that secreted TRACP 5b indicates the number of osteoclasts rather than their activity.
Serum, Osteoclast Cell Culture media
Store the complete kit at 2-8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
- Derived exclusively from bone-resorbing osteoclasts
- Low diurnal variation
- No dietary influences
- No accumulation into the circulation in renal or hepatic failure
- Only bone resorption marker useful in renal research and for non-fasting samples
- A complete assay panel supporting bone research
Bone and cartilage metabolism, Animal studies
TRAP 5 (serum band 5 tartrate-resistant acid phosphatase, TRACP 5; EC 220.127.116.11) is a glycoprotein of 35–37 kDa. TRAP 5 belongs to the most abundant enzymes in osteoclasts. It is expressed in certain differentiated cells of the mononuclear phagocyte system, particularly osteoclasts and alveolar macrophages, where it takes an active part in bone resorption process. High blood levels of TRAP 5 are usually associated with active bone remodelling. Increased serum levels are observed during normal bone growth among healthy children. Elevated serum TRAP levels have been detected in diseases characterized by increased bone resorption; Paget’s disease of the bone, hemodialysis, primary hyperparathyroidism, metastatic malignancies involving bone resorption, multiple myeloma and bilaterally ovariectomized women. Post-menopausal women have higher levels of serum than post-menopausal women on estrogen replacement therapy. Therefore specific determination of TRAP 5 activity can be essential for clinical assessment of bone metabolism.